Novartis: Gilenya gets back on track with NICE approval
This article was originally published in Scrip
Safety concerns and high price points have previously limited use of Novartis’s Gilenya (fingolimod) in the European multiple sclerosis market since its launch in January 2011. However, the decision by the UK's NICE to recommend Gilenya for active relapsing-remitting multiple sclerosis will support the product's future sales which are estimated to reach $2.2 billion across the seven major markets by 2020.
You may also be interested in...
Perampanel has become the first AMPA receptor antagonist to gain approval for the adjunctive treatment of partial-onset seizures. Despite underwhelming clinical trial data and relatively late market entry, perampanel's novel class, convenient dosing regimen, and preferable side-effect profile will support its uptake in the refractory patient population.
The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.
Positive top-line results from the first European Phase III study of Shire’s Vyvanse in children and adolescents with attention deficit hyperactivity disorder (ADHD) is likely to support the product's EU approval. However, given the competition in ADHD from Johnson & Johnson’s well-established Concerta, and the lower drug treatment rates for ADHD in Europe, the growth potential for Vyvanse may lie in the extension of indications beyond ADHD.